Showing results (131-140 of 203) with videos related to
Sort By:
Pageof 21
The Lancet. Oncology|February 28, 2009
Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient dataStefan Michiels, Aurélie Le Maître, Marc Buyse, et al.Journal of the National Cancer Institute|September 27, 2015
The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP), Christopher Sweeney, Mari Nakabayashi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2004
Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancerVéronique Diéras, Pierre Fumoleau, Gilles Romieu, et al.Future Oncology (London, England)|June 18, 2024
End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?Evgeny Degtyarev, Natacha Bolaños, Joshua D Brody, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2023
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyChristophe Tournigand, Thierry André, Emmanuel Achille, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2003
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR studyChristophe Tournigand, Thierry André, Emmanuel Achille, et al.Leukemia|February 13, 2020
ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemiaDenis Claude Roy, Irwin Walker, Johan Maertens, et al.Nature Clinical Practice. Oncology|October 5, 2006
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trialJan Bogaerts, Fatima Cardoso, Marc Buyse, et al.Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|February 14, 2009
Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISHChristine Desmedt, Jeff Sperinde, Fanny Piette, et al.JAMA Oncology|October 6, 2022
Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and MisinterpretationsFabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.Pageof 21